This therapeutic approach targets glucocorticoid receptor (GR/NR3C1) signaling to restore hypothalamic-pituitary-adrenal (HPA) axis homeostasis and protect against cortisol-mediated neurotoxicity. Chronic glucocorticoid dysregulation is a fundamental driver of neurodegeneration across Alzheimer's disease, Parkinson's disease, and ALS.
| Dimension |
Score |
Rationale |
| Novelty |
8/10 |
GR modulation is well-established in psychiatry, but CNS-selective GR modulators for neurodegeneration represent a novel application. First-in-class for this indication. |
| Mechanistic Rationale |
9/10 |
Extensive mechanism: cortisol-mediated excitotoxicity, mitochondrial dysfunction, neuroinflammation, synaptic loss, tau phosphorylation. GR is druggable with existing ligands. |
| Root-Cause Coverage |
8/10 |
Addresses upstream HPA axis dysregulation, not just downstream symptoms. GR is a nuclear receptor with transcriptional activity affecting hundreds of neuroprotective genes. |
| Delivery Feasibility |
6/10 |
Blood-brain barrier penetration is challenging but achievable with selective GR modulators (e.g., CORT108297, RU-28318). Existing compounds from stress research. |
| Safety Plausibility |
7/10 |
GR antagonists have been used in Cushing's syndrome. Side effects (adrenal insufficiency, mood effects) are manageable with careful dosing. |
| Combinability |
8/10 |
Synergistic with NRF2 activators, mitochondrial protectants, anti-inflammatory approaches. Addresses stress-amplified pathology. |
| Biomarker Availability |
7/10 |
Cortisol levels (saliva, serum), dexamethasone suppression test, GR translocation assays in peripheral monocytes. |
| De-risking Path |
7/10 |
Pre-existing GR ligands enable fast translation. Phase 2 trials in depression provide safety data. |
| Multi-disease Potential |
8/10 |
High relevance for AD, PD, ALS, FTD, and normal aging. HPA axis dysfunction is cross-disease. |
| Patient Impact |
7/10 |
Addresses a modifiable pathway (chronic stress) with potential for both disease modification and symptom improvement. |
- Alzheimer's Disease: 8/10 — Cortisol elevation correlates with cognitive decline; GR modulation protects against Aβ and tau synergy
- Parkinson's Disease: 7/10 — Cortisol dysregulation in PD patients; GR protection of dopaminergic neurons
- ALS: 7/10 — GR activation promotes neuroinflammation; antagonism reduces microglial activation
- FTD: 6/10 — GR signaling intersects with tau and TDP-43 pathology
- Aging: 8/10 — Age-related HPA axis dysregulation ("glucocorticoid cascade") is a fundamental aging mechanism
flowchart TD
A["Stress<br/>Stimulus"] --> B["Hypothalamus<br/>CRH Release"]
B --> C["Pituitary<br/>ACTH Release"]
C --> D["Adrenal Cortex<br/>Cortisol Release"]
D --> E["Cortisol<br/>Crosses BBB"]
E --> F["Glucocorticoid<br/>Receptor"]
F --> G["GR Nuclear<br/>Translocation"]
G --> H["Gene Transcription"]
H --> I["Pathological Effects"]
I --> I1["Excitotoxicity<br/>NMDA Enhancement"]
I --> I2["Mitochondrial<br/>Dysfunction"]
I --> I3["Neuroinflammation<br/>NF-κB Activation"]
I --> I4["Synaptic Loss<br/>LTP Inhibition"]
I --> I5["Tau Phosphorylation<br/>GSK-3β Activation"]
J["11β-HSD1<br/>Inhibitor"] -->|"Block Cortisol<br/>Regeneration"| E
K["GR<br/>Antagonist"] -->|"Block GR<br/>Signaling"| F
style I1 fill:#ffcdd2,stroke:#333
style I2 fill:#ffcdd2,stroke:#333
style I3 fill:#ffcdd2,stroke:#333
style I4 fill:#ffcdd2,stroke:#333
style I5 fill:#ffcdd2,stroke:#333
style J fill:#c8e6c9,stroke:#333
style K fill:#c8e6c9,stroke:#333
Excess cortisol enhances NMDA receptor activity and reduces GABAergic inhibition, leading to calcium overload and excitotoxic cell death. GR modulators restore excitatory/inhibitory balance.
Cortisol suppresses mitochondrial biogenesis and promotes permeability transition pore opening. GR antagonism preserves mitochondrial function and ATP production.
GR has complex effects on inflammation — while anti-inflammatory in some contexts, chronic activation promotes NF-κB and NLRP3 activation. Selective modulation shifts toward anti-inflammatory transcription (transrepression vs transactivation).
Cortisol impairs LTP and dendritic spine density in the hippocampus. GR modulators restore synaptic plasticity genes (BDNF, CREB) and preserve memory circuits.
Cortisol activates GSK-3β and CDK5, accelerating tau pathology. GR modulation reduces pathological tau phosphorylation.
- CORT108297: Brain-penetrant GR antagonist, protects against chronic stress-induced neurodegeneration
- RU-486 (Mifepristone): FDA-approved for Cushing's syndrome, being explored for GR in AD
- Mifepristone + SSRIs: Combination approach for comorbid depression and neurodegeneration
- Carbenoxolone: Inhibits 11β-HSD1 to reduce active cortisol in brain; shown to improve memory in elderly subjects
- Firibastat (ABI-HF001): Selective 11β-HSD1 inhibitor in Phase 2 for AD (NCT04014434) — first-in-class for neurodegeneration
- Xanamem (AZD1390): 11β-HSD1 inhibitor in Phase 2 (NCT06125951) by Actinogen Medical — 247 patients, doses 10/20/40mg daily
- Rationale: Prevents cortisol regeneration in brain without blocking systemic GR, avoids HPA axis disruption[@seckl2023][@actinogen2024][@firibastat_trial]
| Compound |
Mechanism |
BBB Penetration |
CNS Exposure (AUC brain/plasma) |
Development Stage |
| CORT108297 |
GR antagonist |
High |
~0.8 |
Phase 2 (NCT04601038) |
| Mifepristone |
GR antagonist |
Moderate |
~0.3 |
Phase 2 in AD |
| Firibastat (ABI-HF001) |
11β-HSD1 inhibitor |
Moderate |
~0.4 |
Phase 2 (NCT04014434) |
| Xanamem |
11β-HSD1 inhibitor |
Moderate |
~0.5 |
Phase 2 (NCT06125951) |
| Carbenoxolone |
11β-HSD1 inhibitor |
Low |
~0.15 |
Clinical use (ulcer therapy) |
| RU-28318 |
GR agonist |
High |
~0.9 |
Research use |
- Compound 2 (C2): Selective GR modulator with neuroprotective profile
- Tebufone: Non-steroidal GR modulator with improved BBB penetration
- Rationale: Achieve transrepression (anti-inflammatory) without transactivation (side effects)
- PU91: GR coactivator interaction inhibitor
- Rationale: Modulate GR transcriptional activity without affecting ligand binding
- Validate GR expression in patient iPSC-derived neurons and post-mortem brain tissue
- Test GR modulators in 3xTG-AD and α-synuclein transgenic mice
- Establish cortisol and GR translocation biomarkers
- Evaluate blood-brain barrier penetration of GR modulators in non-human primates
- Optimize dosing for CNS GR occupancy (PET ligands available)
- Assess combination with standard-of-care (AChEIs, levodopa)
- Phase 1 safety in healthy volunteers with CNS PK assessments
- Phase 2 proof-of-concept in AD (cortisol-positive subgroup) and PD
- Biomarker-driven patient enrichment (elevated cortisol, HPA axis dysfunction)
| Risk |
Mitigation |
| Peripheral GR effects |
Use brain-selective compounds or 11β-HSD1 inhibitors |
| Adrenal insufficiency |
Careful titration, stress-dose steroids for emergencies |
| Mood effects |
Start low, monitor with validated scales |
| Drug-drug interactions |
Screen for CYP3A4 interactions with existing neurodegeneration drugs |
- Basal cortisol (morning serum, elevated in ~40% of AD/PD patients)
- Dexamethasone suppression test (impaired in HPA axis dysregulation)
- Cortisol/DHEA ratio (low DHEA indicates vulnerability)
- GR translocation (flow cytometry of peripheral monocytes)
- Salivary cortisol AUC (diurnal curve assessment)
- GR Modulator + NRF2 Activator: Address oxidative stress from multiple angles
- GR Modulator + Mitochondrial Protectant: Combined mitochondrial protection
- GR Modulator + Anti-amyloid: Reduce cortisol-driven Aβ production
- GR Modulator + Exercise: Enhance stress resilience and neurogenesis
- Sapolsky et al., Glucocorticoids and neurodegeneration (2023)
- McEwen et al., Stress and the brain (2024)
- Csordas et al., Cortisol in Alzheimer's disease (2023)
- Foltynie et al., Cortisol in Parkinson's disease (2019)
- De Kloet et al., 11β-HSD1 in brain function (2020)
- Holsboer, Glucocorticoid receptor function (2022)
- Lupien et al., Cortisol levels during human aging predict hippocampal atrophy (1998)
- Seckl et al., 11β-Hydroxysteroid dehydrogenase in the brain (2023)
- O'Brien et al., Glucocorticoids and brain atrophy in AD (2024)
- Holmes et al., 11β-HSD1 as therapeutic target in CNS disorders (2023)
- Yau et al., Hippocampal glucocorticoid metabolism in aging and AD (2023)
- Hershey et al., 11β-HSD1 activity and cognitive function in aging (2023)
- Actinogen Medical, Xanamem Phase 2 AD Trial (NCT06125951)
- Firibastat (ABI-HF001) Phase 2 Trial (NCT04014434)